# Kosmos Pilot Test

**Date:** December 9, 2025  

---

## Executive Summary

This report documents a pilot testing system designed to evaluate Kosmos. 

**Key Achievement:** Designed and executed a comprehensive testing framework across five computational biology domains, with automated metrics for evaluating AI-generated content accuracy and utility.

**Current Status:** All 28 experiments completed, with the pilot study's 5 core experiments finished. Success rate: 22/28 successful, 5 failed, 1 pending at the time of writing.

**Overall Pilot Results:**
- Tasks 3 & 4 (ANALYSIS & MOLECULES): ‚úÖ Perfect scores
- Tasks 1, 2, 5 (LITERATURE & PRECEDENT): Mixed results with valuable insights
- All technical challenges overcome with workarounds (see below)

**Personal Note:** The UI quality is crucial for Kosmos's future success. While Claude Code may have superior coding capabilities, having an interface that's easier to use than standard CLI-based tools will be key to making the scientific journey easier. The reason I'm personally loving this journey with Kosmos is that it presents me with a UI that is actively TRYING to simplify things and analysis. If the UI becomes even more magical, I may actually start using it for my experiments.

---

## 5. Experimental Results: All Five Domains Complete

The pilot study is complete with all five experiments successfully executed and evaluated. The results reveal clear strengths and areas for improvement:

**Success Summary:**
- ‚úÖ **ANALYSIS (Systems Biology):** Perfect performance in RNA-seq analysis
- ‚úÖ **MOLECULES (Structural Biology):** Outstanding computational drug design
- ‚ö†Ô∏è **LITERATURE (Cancer Genomics):** Good synthesis, citation issues
- ‚ö†Ô∏è **PRECEDENT (Immunology):** Correct answers, trial identification challenges
- ‚ö†Ô∏è **LITERATURE (Neuroscience):** Excellent synthesis, terminology mismatch

Below are detailed findings from each domain:

### 5.1. Task 1: Cancer Genomics (LITERATURE)
**[üìä View Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task1_results/task1_report_executive.md)** |
**[üîó View Kosmos Platform](https://platform.edisonscientific.com/trajectories/561fb2fd-06c8-4a17-9ce8-9e4020f09aa0)**

**Key Results:**
- Status: ‚ùå FAIL overall (3/4 metrics failed)
- Target Recall: 60% (found 3/5 known targets: MRTX1133, SHP2, SOS1)
- Citation Count: Only 6 citations (target: ‚â•20)
- **Success:** 100% citation validity, perfect resistance mechanism coverage
- **Missed:** MRTX849 (FDA-approved), key 2023 Nature papers

**What Kosmos Found:**
- Identified daraxonrasib (RMC-6236) - novel pan-RAS inhibitor
- Provided 12 active NCT trial IDs
- Comprehensive resistance mechanism synthesis

**Technical Issues:**
- Provided clinical trial IDs instead of research paper DOIs
- Ground truth mismatch: focused on trials over foundational papers

### 5.2. Task 2: Immunology (PRECEDENT)
**[üìä View Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task2_results/task2_report_executive.md)** |
**[üîó View Kosmos Platform](https://platform.edisonscientific.com/trajectories/9e573c63-aa7d-4f79-adc3-501ffc4ba279)**

**Key Results:**
- Status: ‚ùå FAIL overall (2/4 metrics failed)
- Precedent Accuracy: ‚úÖ 100% (correctly identified vaccines exist)
- NCT Trial Recall: ‚ùå 0% (didn't find specific trial IDs)
- Enhanced Recall: 33.3% (found mRNA-4157 but missed others)

**What Kosmos Found:**
- mRNA-4157 (Moderna) - Phase 2b data: improved RFS (HR 0.56)
- Autogene cevumeran (BioNTech) - Phase I: 50% T-cell response rate
- Detailed efficacy and safety outcomes

**Technical Issues Fixed:**
- API returns "success" not "completed" status
- Enhanced evaluation to recognize product names, not just NCT IDs

### 5.3. Task 3: Systems Biology (ANALYSIS)
**[üìä View Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task3_results/task3_report_executive.md)** |
**[üîó View Kosmos Platform](https://platform.edisonscientific.com/trajectories/86d6c8a2-9d7c-42d6-abc7-bd40f2d46474)**

**Key Results:**
- Status: ‚úÖ PASS (all 4 metrics passed!)
- Gene Recall: 100% (all 8 canonical heat shock genes identified)
- Code Execution: ‚úÖ Complete R/DESeq2 analysis notebook
- Figure Count: 3/3 (volcano plot, heatmap, bar plot)
- Hypothesis Quality: 100% (all 3 hypotheses biologically relevant)

**What Kosmos Found:**
- 13 significant DEGs (8 upregulated chaperones)
- Fold changes: dnaK (4.0x), groEL (5.9x), ibpB (4.9x)
- Three testable hypotheses about chaperone regulation

**Technical Issues Fixed:**
- File uploads fail with ANALYSIS jobs
- Implemented inline data workaround
- Successfully demonstrated full capability without uploads

### 5.4. Task 4: Structural Biology (MOLECULES)
**[üìä View Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task4_results/task4_report_executive.md)** |
**[üîó View Kosmos Platform](https://platform.edisonscientific.com/trajectories/46d09be4-cbe6-4138-837e-54766594fd4a)**

**Key Results:**
- Status: ‚úÖ PASS (all 4 metrics passed!)
- Chemical Validity: 100% (all 3 molecules have valid SMILES)
- Property Improvement: 100% (all show ‚â•1 improved property)
- ADMET Completeness: 100%
- Synthesis Routes: 100% (all include retrosynthesis)

**What Kosmos Designed:**
- **Molecule 1:** 185,768 Œºg/mL solubility (vs 135 for nirmatrelvir)
- **Molecule 3:** 792,447 Œºg/mL solubility (dramatic improvement)
- All maintained reasonable bioavailability (32-47% vs 50% baseline)
- SAScores 4.45-4.53 (synthetically accessible)

**Technical Issues Fixed:**
- API uses "answer" field not "result" field
- Custom parser for molecular properties
- Converted logS to Œºg/mL for proper comparison

### 5.5. Task 5: Neuroscience (LITERATURE)
**[üìä View Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task5_results/task5_report_executive.md)** |
**[üîó View Kosmos Platform](https://platform.edisonscientific.com/trajectories/0ee36475-e575-4d67-9e14-dbdfd97103dd)**

**Key Results:**
- Status: ‚ùå FAIL overall (2/4 metrics failed)
- Mechanism Recall: 25% (1/4 established mechanisms)
- **Intervention Ranking:** ‚úÖ Perfect (œÑ=1.00 correlation)
- Citation Count: 14 (just 1 short of target)
- Primary Research: 100% (all citations primary sources)

**What Kosmos Found:**
- LPS-induced neuroinflammation via TLR4/NF-Œ∫B pathway
- Perfect intervention feasibility ranking:
  1. Diet/pre/probiotics (RCTs available)
  2. SIBO/H. pylori management
  3. FMT (pilot studies)
  4. Vagal neuromodulation (exploratory)
- Excellent cross-domain synthesis quality

**Technical Issues:**
- Terminology differences from ground truth
- Fuzzy matching needed for equivalent mechanisms

### 5.6. Overall Pilot Assessment

**Success Rate:** 2/5 tasks passed all metrics (40%)

**Key Insights:**

**Strengths of Kosmos:**
1. **Technical Capabilities:** High performance in ANALYSIS and MOLECULES tasks
   - Complete RNA-seq analysis with executable R/DESeq2 code (100% gene recall)
   - Chemically valid molecular structures with improved solubility profiles
   - Generation of biologically relevant, testable hypotheses

2. **Integration Value:** Demonstrated ability to combine multiple capabilities
   - Literature synthesis effectively linked to experimental design
   - Cross-domain knowledge integration (microbiology + neuroscience)
   - Clinical trial awareness and outcome reporting

3. **User Experience:** UI reduces complexity of scientific workflows
   - Lowers technical barriers for non-programmer scientists
   - Provides integrated scientific tools (vs. separate CLI tools)
   - Interactive visualizations and real-time feedback

**Areas for Improvement:**
1. **Citation Quality:** Need for DOI-based research paper citations
2. **Terminology Standardization:** Better alignment with established nomenclature
3. **Ground Truth Coverage:** More comprehensive literature review
4. **API Consistency:** Standardized response formats across job types

**Business Implications:**
- Strong value proposition for computational tasks
- Literature synthesis needs refinement for grant writers
- Package approach clearly superior to DIY solutions
- Trust-building through verification essential

---

## 11. Conclusion

This pilot demonstrates that rigorous evaluation of AI tools for scientific research is not only possible but essential. The initial hands-on experience with Kosmos showed impressive capabilities in medical AI research, with execution patterns reminiscent of advanced Claude Code environments enhanced by specialized academic integrations.

However, the technical complexity required to build such systems creates a significant barrier for most scientists. This implementation gap underscores why rigorous evaluation of commercial AI tools like Kosmos is crucial - they may represent the only viable path for many researchers to access these capabilities.

By applying software engineering best practices (TDD, automation, parallel execution) to scientific validation, we've created a framework that can scale to larger studies and provide the evidence base needed for informed AI adoption in science.

The immediate success in implementing this framework, combined with the progress on the actual experiments, provides strong confidence that the full RCT will yield valuable insights into how AI tools can transform scientific research productivity and quality.

**Key takeaways for business school perspective:**
- Clear methodology for evaluating AI productivity tools
- Demonstrated cost-benefit analysis framework
- Insights into technology adoption in knowledge work
- Model for evidence-based AI implementation strategies

---

## Appendix: Technical Details

### A. Links to Full Executive Reports

1. **Task 1: Cancer Genomics**
   - [Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task1_results/task1_report_executive.md)
   - [Kosmos Platform](https://platform.edisonscientific.com/trajectories/561fb2fd-06c8-4a17-9ce8-9e4020f09aa0)

2. **Task 2: Immunology**
   - [Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task2_results/task2_report_executive.md)
   - [Kosmos Platform](https://platform.edisonscientific.com/trajectories/9e573c63-aa7d-4f79-adc3-501ffc4ba279)

3. **Task 3: Systems Biology**
   - [Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task3_results/task3_report_executive.md)
   - [Kosmos Platform](https://platform.edisonscientific.com/trajectories/86d6c8a2-9d7c-42d6-abc7-bd40f2d46474)

4. **Task 4: Structural Biology**
   - [Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task4_results/task4_report_executive.md)
   - [Kosmos Platform](https://platform.edisonscientific.com/trajectories/46d09be4-cbe6-4138-837e-54766594fd4a)

5. **Task 5: Neuroscience**
   - [Executive Report](https://github.com/sergeicu/kosmos-v1/blob/main/output/task5_results/task5_report_executive.md)
   - [Kosmos Platform](https://platform.edisonscientific.com/trajectories/0ee36475-e575-4d67-9e14-dbdfd97103dd)

### B. Evaluation Code Snippets

```python
# Citation validation
def validate_citations_sample(citations, n=5):
    sample = random.sample(citations, min(n, len(citations)))
    valid = sum(1 for c in sample if verify_doi_exists(c))
    return valid / len(sample)

# Chemical validity check
def validate_smiles(smiles_str):
    mol = Chem.MolFromSmiles(smiles_str)
    return mol is not None

# Ranking quality assessment
def evaluate_intervention_ranking(kosmos_ranking, expected_order):
    tau, _ = kendalltau(kosmos_ranking, expected_order)
    return tau
```

### C. Budget Breakdown

| Item | Cost |
|------|------|
| Kosmos API usage (5 √ó $200) | $1,000 |
| Development time (pilot) | $5,000 (in-kind) |
| Cloud infrastructure | $50 |
| Citation verification (CrossRef) | Free |
| Total pilot cost | ~$6,050 |

### D. Timeline Summary

| Phase | Duration | Status |
|-------|----------|---------|
| Design & ground truth prep | 2 weeks | Complete |
| Phase 0: API testing | 30 min | Complete |
| Phase 1: Job validation | 30 min | Complete |
| Phase 2: Experiments | 2 hours | Complete |
| Analysis & reporting | 1 week | Complete |
| Total | 4 hours active + prep | 100% Complete |

---

## 6. Connection to Full RCT: Why This Pilot Matters

### 6.1. De-risking the Main Study

This pilot addresses critical risks before the 10-15 participant RCT:

1. **Technical risk:** ‚úì API access works
2. **Evaluation risk:** ‚úì Metrics framework validated
3. **Cost risk:** ‚úì Budget estimation refined ($200/experiment)
4. **Time risk:** ‚úì 2-hour execution window feasible
5. **Relevance risk:** ‚úì Tasks map to real research needs

### 6.2. Scaling Considerations

**From Pilot (5 experiments) to RCT (10-15 scientists):**

| Aspect | Pilot | RCT Scale | Scaling Factor |
|--------|-------|-----------|----------------|
| Experiments | 5 | 50-75 | 10-15x |
| Cost | $1,000 | $10,000-15,000 | Linear |
| Evaluation | Automated | Mixed auto/manual | Added human review |
| Domains | 5 | 5 (consistent) | None |
| Duration | 4 hours | Multi-week | Extended timeline |

### 6.3. Key RCT Questions Informed by Pilot

**Question 1: Productivity Impact**
- Pilot establishes baseline task completion times
- Identifies which tasks benefit most from AI assistance
- Provides metrics for productivity measurement

**Question 2: Quality Assessment**
- Pilot shows AI can identify correct scientific concepts
- Reveals need for human expert validation
- Demonstrates importance of citation verification

**Question 3: User Experience**
- Parallel execution model scales to multiple users
- Clear file organization prevents confusion
- Comprehensive logging supports research compliance

---

## 7. Implications for Business School Research

### 7.1. Innovation Management

This study demonstrates:
- **Technology adoption patterns:** How scientists integrate AI tools
- **Productivity measurement:** Framework for evaluating AI impact
- **Risk mitigation:** TDD approach for AI system validation

### 7.2. ROI Analysis for Scientific AI

**Cost Structure:**
- Development: Pilot framework ($5,000 estimated)
- Per-use: $200/experiment
- Evaluation: Automated (minimal marginal cost)
- Expert review: $100/experiment (estimated)

**Value Proposition:**
- Time savings: 4-8 hours/experiment (estimated)
- Success rate improvement: To be measured in RCT
- Grant competitiveness: Qualitative benefit to quantify

### 7.3. Market Insights

**Demand Signals:**
- High need for literature synthesis tools
- Gap in data analysis automation
- Critical need for validation and verification

**Competitive Landscape:**
- Kosmos vs. specialized tools (e.g., AlphaFold, ChemAxon)
- Integration challenges across domains
- Opportunity in workflow orchestration

---

## 8. Recommendations

### 8.1. For the Full RCT

1. **Scale the framework:** Use pilot infrastructure for larger study
2. **Add human experts:** Domain scientists for qualitative review
3. **Include control group:** Traditional research methods vs. AI-assisted
4. **Track long-term:** Grant outcomes, not just proposal quality

### 8.2. For Edison/Kosmos Product Development

1. **Citation verification:** Build in real-time validation
2. **Domain specialization:** Tailor outputs to grant writing needs
3. **Uncertainty quantification:** Report confidence in predictions
4. **Integration focus:** Better workflow with existing tools

### 8.3. For Scientific Community

1. **Validation standards:** Community-wide AI output verification
2. **Reproducibility:** Share evaluation frameworks openly
3. **Training:** Scientists need AI literacy programs
4. **Ethics:** Guidelines for AI attribution in grants

---

## 9. Conclusion

This pilot demonstrates that rigorous evaluation of AI tools for scientific research is not only possible but essential. The initial hands-on experience with Kosmos showed impressive capabilities in medical AI research, with execution patterns reminiscent of advanced Claude Code environments enhanced by specialized academic integrations.

However, the technical complexity required to build such systems creates a significant barrier for most scientists. This implementation gap underscores why rigorous evaluation of commercial AI tools like Kosmos is crucial - they may represent the only viable path for many researchers to access these capabilities.

By applying software engineering best practices (TDD, automation, parallel execution) to scientific validation, we've created a framework that can scale to larger studies and provide the evidence base needed for informed AI adoption in science.

The immediate success in implementing this framework, combined with the progress on the actual experiments, provides strong confidence that the full RCT will yield valuable insights into how AI tools can transform scientific research productivity and quality.

**Key takeaways for business school perspective:**
- Clear methodology for evaluating AI productivity tools
- Demonstrated cost-benefit analysis framework
- Insights into technology adoption in knowledge work
- Model for evidence-based AI implementation strategies

---
